<DOC>
	<DOCNO>NCT00075608</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth plasma cell , either kill cell stop divide . Having stem cell transplant replace blood-forming cell destroy chemotherapy , allow high dos chemotherapy give plasma cell kill . By reduce number plasma cell , disease may progress slowly . PURPOSE : This phase II trial study well autologous stem cell transplant work treat patient persistent recurrent primary systemic ( AL ) amyloidosis .</brief_summary>
	<brief_title>2nd Autologous Stem Cell Transplant Patients With Persistent/Recurrent ( AL ) Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility tolerability second autologous stem cell transplantation patient persistent recurrent AL amyloidosis . - Determine response rate durability response patient treat regimen . - Determine immune reconstitution patient treat regimen . OUTLINE : - Mobilization : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin initiation stem cell collection continue day completion stem cell collection . - Preparative regimen : Patients receive high-dose melphalan IV 20 minute day -3 -2 . - Autologous stem cell transplantation : Autologous stem cell reinfused day 0 . Patients follow 6 month , 1 year , annually thereafter . PROJECTED ACCRUAL : A total 19 patient accrue study within 5-6 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion criterion : DISEASE CHARACTERISTICS : Histologically confirm AL amyloidosis Persistent recurrent disease 1 course prior highdose chemotherapy Previously treat autologous stem cell transplantation Significant initial improvement organ function prior highdose melphalan , define least 1 follow : Complete hematologic remission ( e.g. , absence monoclonal spike immunofixation serum urine AND le 5 % plasma cell bone marrow clonal predominance ) OR partial hematologic response ( e.g. , decrease serum urine monoclonal protein OR decrease bone marrow plasmacytosis ) Greater 50 % reduction proteinuria preservation creatinine clearance Greater 50 % reduction alkaline phosphatase OR least 2 cm decrease liver size physical exam Subjective neurologic improvement , confirm neurologist Cardiac stabilization disease confirm echocardiography define less 2 mm increase mean wall thickness and/or less 20 g increase leave ventricular mass Improvement performance status* NOTE : *This criterion alone constitute significant improvement organ function Prior stem cell yield must ≥ 2 x 10^6 CD34+ cells/kg PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics No chemotherapy first transplantation Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify PATIENT CHARACTERISTICS : Age 18 65 Performance status Southwest Oncology Group 02 Life expectancy More 6 month Hematopoietic See Disease Characteristics Hepatic See Disease Characteristics Renal See Disease Characteristics Cardiovascular See Disease Characteristics Left ventricular ejection fraction ≥ 45 % multiple gated acquisition scan echocardiogram Pulmonary diffusing capacity lung carbon monoxide ≥ 50 % No myelodysplastic syndromes No abnormal bone marrow cytogenetics Other Not pregnant nursing Fertile patient must use effective contraception Acceptable toxicity first transplantation , confirm transplant team HIV negative No concurrent malignancy except treated skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>